Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01486459 : A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Histologically or cytologically confirmed high grade small cell neuroendocrine
carcinoma.

- Patients can either have:

- Limited stage disease with CR or PR OR

- Extensive stage disease with CR or good PR

- Patients must have discontinued other chemotherapies at least 3 weeks prior to
randomisation.

- Prior radiation therapy to the chest is allowed but must be completed at least 3
weeks prior to randomisation.

- ECOG Performance Status 0 to 2.

- Adequate bone marrow, liver, and renal function as assessed by the following:

- Hemoglobin ? 9.0 g/dl

- Absolute neutrophil count (ANC) ? 1,500/mm3

- Platelet count ? 100,000/mm3

- Total bilirubin ? 2.0 times the upper limit of normal

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x
upper limit of normal (? 5x ULN for patients with liver involvement)

- International Normalized Ratio for Prothrombin Time (PT-INR) ? 1.5 and activated
partial prothrombin time (aPTT) within 5% of normal limits for patient NOT on
anticoagulation.

- Estimated Glomerular Filtration Rate (eGRF) > 50 ml/min .

- Male or female aged >18 years

- Patients must be able and willing to sign a written informed consent. A signed
informed consent must be appropriately obtained prior to any study specific
procedures.

- Patients must be able to swallow and retain oral medication.

- Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to randomisation and must agree to use adequate contraception
prior to randomisation and for the duration of study participation.

Exclusion Criteria:

- Life expectancy less than 3 months.

- Substance abuse, medical, psychological, or social condition that may interfere with
the patient's participation in the study or evaluation of the study results.

- Severe cardiac or renal disease.

- Frank hypothyroidism.

- Hyponatraemia.

- Known or suspected allergy to lithium.

- Women who are pregnant or breast-feeding.

- Inability to comply with protocol and /or not willing or not available for follow-up
assessments.

- Significant psychiatric or neurologic illness (prior known psych/cognitive/CNS
pathology eg CVA; known or prior brain metastases

- Current lithium therapy.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01486459      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740